Skip to main content
. 2019 Sep 4;9:866. doi: 10.3389/fonc.2019.00866

Figure 3.

Figure 3

Forest plots for the odds ratio of treatment related peripheral neuropathy for grade 3–5. (A1) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Docetaxel/Paclitaxel). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups. (A2) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. monotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. (B1) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. (B2) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups. (C1) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. (C2) Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups.